Brain Cancer Clinical Trials in Arizona

Showing 141-160 of 182 trials

Multi-site Validation and Application of a Consensus DSC-MRI Protocol

NCT03401866

This clinical trial is to validate and demonstrate the clinical usefulness of a protocol for Magnetic Resonance Imaging (MRI) in people with high grade glioma brain tumors.

Glioblastoma MultiformeGliosarcoma

St. Joseph's Hospital and Medical Center, Phoenix80 participantsStarted Feb 2018

Scottsdale, Arizona, United States • Providence, Rhode Island, United States • Milwaukee, Wisconsin, United States

TERMINATEDPhase 231 miles

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

NCT01340794

This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced or progressive malignant pheochromocytoma or paraganglioma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Extra-Adrenal ParagangliomaMetastatic Adrenal Gland PheochromocytomaParaganglioma+1 more

National Cancer Institute (NCI)7 participantsStarted May 2011

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Baltimore, Maryland, United States +8 more locations

Multi-site Validation and Application of a Consensus DSC-MRI Protocol

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Brain Cancer Trials in Other Cities

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma

Expanded Access to ANG1005 for Individual Patients

A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Pazopanib in Treating Patients With Recurrent Glioblastoma

A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma

AMG 595 First-in-Human in Recurrent Gliomas

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

MK-2206 for Recurrent Malignant Glioma

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme

Other Conditions in Arizona